Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and ShadowsMaria Chianese, Barbara Ruaro, Marco Confalonieri et al.|Pharmaceuticals|2024Cited by 86
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary FibrosisStefano Kette, Barbara Ruaro, Alessia Giovanna Andrisano et al.|Pharmaceuticals|2025Cited by 6